



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	123288	SLIMist
<b>ARTG entry for</b>	Medicine Listed (Export Only)	
<b>Sponsor</b>	Slimist Wholesale Pty Ltd	
<b>Postal Address</b>	Level 23 Tower 1 500 Oxford Street, BONDI JUNCTION, NSW, 2022 Australia	
<b>ARTG Start Date</b>	2/11/2005	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Export only Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . SLIMist

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	2/11/2005
---------------------	-------------------------	-----------------------	-----------

#### Permitted Indications

No Permitted Indications included on Record

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

Slimist spray may assist with weight loss when used in conjunction with a caloric controlled diet and exercise plan.  
Chromium may help

- with carbohydrate metabolism
  - in the regulation of carbohydrate and lipid metabolism.
  - to support thermogenesis via fatty acid oxidation.
  - lower body weight & preserve/promote lean body mass.
- Carnitine is important in the system for energy metabolism.  
It supports the body's ability to use stored fat as fuel for energy.  
It assists in fatty acid metabolism.

#### Warnings

Contains benzoates' (or words to this effect) if the medicine contains two or more benzoate sources or 'Contains [insert the approved name of benzoate used]' (or words to this effect) if product contains one benzoate source.

Contains saccharin sodium (or words to that effect).

#### Additional Product information



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Medicine Component**

**Dosage Form** Oral Liquid

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>chromium nicotinate</b>	<b>113 microgram/mL</b>
Equivalent: chromium	14 microgram/mL
<b>Garcinia quaesita fruit Extract dry concentrate</b>	<b>3.6 mg/mL</b>
Equivalent: Garcinia quaesita	36 mg/mL
Equivalent: hydroxycitric acid	1.8 mg/mL
<b>levocarnitine hydrochloride</b>	<b>277.65 mg/mL</b>

**Other Ingredients (Excipients)**

disodium edetate

Flavour

purified water

saccharin sodium

sodium benzoate

sodium citrate dihydrate

sodium hydroxide

vanillin

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary